Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Immunotherapy of cancer 2

2558 - Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: data from a French multicentric cohort


22 Oct 2018


Poster Discussion session - Immunotherapy of cancer 2



Tumour Site


Charlotte Domblides


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


C. Domblides1, I. Monnet2, J. Mazieres3, F. Barlesi4, V. Gounant5, S. Baldacci6, B. Mennecier7, A.C. Toffart8, C. Audigier Valette9, L. Doucet10, E. Giroux-Leprieur11, F. Guisier12, O. Molinier13, M. Perol14, E. Pichon15, G. Robinet16, D. Templement Grangerat17, A. Ruppert1, M. Wislez1

Author affiliations

  • 1 Pneumology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 2 Pneumology, CH Intercommunal de Créteil, 94010 - Créteil/FR
  • 3 Thoracic Oncology, Hospital Larrey, 31400 - Toulouse/FR
  • 4 Oncology Department, Aix-Marseille University - Faculté de Médecine Nord, 13015 - Marseille/FR
  • 5 Pneumology, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 6 Haut De France, Hopital Calmette, CHRU Lille, 59000 - Lille/FR
  • 7 Pathologie Respiratoire, C.H.U. Strasbourg-Nouvel Hopital Civil, 67000 - Strasbourg/FR
  • 8 Pneumology, CHU de Grenoble, 38700 - La Tronche/FR
  • 9 Pneumology, Hospital Sainte Musse, 83100 - Toulon/FR
  • 10 Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 11 Pneumology, Hopital Ambroise Pare, 92100 - Boulogne-Billancourt/FR
  • 12 Pneumology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 13 Pneumology, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 14 Pneumology, Centre Léon Bérard, 69008 - Lyon/FR
  • 15 Pneumology, CHRU Bretonneau, 37044 - Tours/FR
  • 16 Pneumology, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 17 Pneumology, Le Centre Hospitalier Annecy Genevois, 74370 - Metz-Tessy/FR

Abstract 2558


Immune checkpoint inhibitors (ICI) have improved outcomes of non-small cell lung cancer (NSCLC) patients. Previous findings showed that PD-L1 expression and immune-cell infiltration were high in sarcomatoid carcinoma (SC), a rare subset of NSCLC with a poor prognosis. This study sought to retrospectively assess the efficacy of ICI in SC.


All consecutive patients (pts) with stage III or IV confirmed SC (reviewed by a specialized pathologist) receiving at least one dose of an ICI between 2011 and 2017 were enrolled. PD-L1 was considered positive if higher than 1%.


Forty-two centres participated to the study and 27 included 39 patients. At diagnosis, they were mostly men (81%), current (41%) or former (53.8%) smokers, with a median age of 63.2 years [36.8-84.6]. Performance status (PS) was 0-1 for 71.8% of them. Sixteen (48.8%) tumours were genotyped, and they were KRAS (38.5%), MET exon 14 (7.7%) or EGFR (2.6%) mutated. Almost all pts (94.9%) received previous platinum-based chemotherapy. ICI were administered as 1st / 2nd / ≥3rd-lines for 5.1% / 51.3% / 43.6%, respectively. Pts received by nivolumab (87.2%), pembrolizumab (7.7%) or atezolizumab (5.1%). Median duration of treatment was 4.5 months [0.5-24]. As best overall response, overall response rate (ORR) was 38.5%, disease control rate (DCR) 61.6% and progressive disease 30.8%. The main reason for ICI discontinuation was progression (69.2%), with a median PFS of 4.59 months [0.3-24.1] and a 1-year-PFS rate of 10.3% (4/39). Five (12.8%) pts died before the first radiologic evaluation under ICI with a median of 0.62 months [0.26-1.51]. Median survival was 20 months [1.7–61.7]. Eighteen pts (46.1%) received a subsequent line (chemotherapy (n = 15) or TKI (n = 3)) with 55.5% progressive disease, 27.8% stable disease and no partial response. PD-L1 status was assessed in 18 tumours (46.1%). In PDL1+ pts, ORR was 53.3% (8/15) and DCR was 66.7% (10/15). ORR and DCR were 33.3% (1/3) for both criteria in PDL1- pts. There was no difference in ORR (p = 0.73), DCR (p = 0.71), PFS (p = 0.34) and OS (p = 0.35) according to KRAS status.


Our results suggest that SC pts may benefit from ICI. We are collecting tumour samples to assess the correlation between response and PD-L1 expression.

Clinical trial identification

Legal entity responsible for the study

Assistance Publique - Hôpitaux de Paris..


Has not received any funding.

Editorial Acknowledgement


C. Domblides: Speaker: AstraZeneca; Travel: Pierre Fabre, AstraZeneca, Pfizer, Amgen, MSD, Roche; Research funding: AstraZeneca. J. Mazieres: Consulting or advisory role: AstraZeneca, Roche, BMS, MSD, Novartis, Pfizer; Research funding: AstraZeneca, Roche, BMS; Travel, accommodations, expenses: Roche, BMS, Novartis, Pfizer. S. Baldacci: Personal fees: Lilly, GSK, Pfizer, Roche for activities outside the written work. A.C. Toffart: Membership on advisory board: BMS, MSD; Speaker: AstraZeneca; Grant: Roche; Travel: BMS, Roche. C. Audigier Valette: Clinical trials as principal investigator: AstraZeneca, Boehringer Ingelheim, BMS, Novartis, Roche; Advisory board: AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Novartis, MSD, Pfizer, Roche; Conferences and interventions: AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Novartis, Pfizer, Roche. E. Giroux-Leprieur: Advisory board: AstraZeneca, Bristol-Myers Squibb, Novartis, Roche; Research grants: AstraZeneca, Bristol-Myers-Squibb, Roche. F. Guisier: Honoraria for consulting and advisory boards: BMS, MSD, Roche, AstraZeneca, Boehringer Ingelheim; Travel support: Chugai; Investigator in trials sponsored by: BMS, MSD, Roche, Takeda, Merrimack Pharmaceuticals, Janssen. M. Perol: Honoraria for Advisory boards and symposia: Bristol-Myers Squibb, Roche, Merck Sharp & Dohme (MSD), AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.